An IgG1 antibody targeting CS1, elotuzumab, has shown impressive in vitro activity against myeloma cells, killing myeloma cells via antibody dependent cellular cytotoxicity (ADCC) while using the same receptor for activation of NK cells [25,26]. Here, SLAMF7 is linked to plasma cell myeloma.